COMPANY

BioCytics

Keywords: oncology cell therapy solid tumors immuno-oncology solid tumor COVID-19 Donors

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $25K (Form D filed Mar 13, 2026). SEC Form D 0001971839-26-000001 (Mar 13, 2026)
Evidence (1 event)
- Mar 13, 2026 · SEC Form D 0001971839-26-000001
  Name of Issuer: BioCytics, Inc.; CIK: 1971839; Address: Huntersville, NC; Submission type: D; Filing date: 2026-03-13; Industry Group: Biotechnology; Date of First Sale: 2026-01-02; Types of Securities Offered: Option/warrant; Business combination transaction: false; Total Offering Amount: 7000000; Total Amount Sold: 25000; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

2007-11 Trial start —: A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. source ↗

2030-02 (ESTIMATED) · · A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells. · NCT00571389

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT00571389	A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.	Not listed	Recruiting	2007-11	2030-02 (estimated)